Many of the bill's provisions specifically related to the biopharmaceutical industry are relatively unchanged from earlier versions that emerged from three House committees. read more
HHS would negotiate rates with providers, with a Medicare floor and average private insurance rates ceiling; CBO anticipates about 6 million public plan enrollees. read more
Independent versus government-based CER group is one of issues likely to be left to House/Senate negotiators. read more
FTC says Schering must divest its NK-1 receptor antagonist relapitant. Merck must also sell its interest in a $2.6 billion animal health joint venture. read more
AstraZeneca has an agreement in principle to resolve government investigation of its antipsychotic promotion and pay $520 million. read more
Uncertainty over aspirin usage among a North American subgroup of trial patients continues to raise speculation about an FDA review. read more
This is Sanofi-Aventis' third oncology partnership this year, as it continues to seek new cancer drugs to replace Taxotere and Eloxatin. read more
Once-weekly human GLP-1 analog taspoglutide shows superior HbA1c reduction to Byetta - and may soon catch Novo's liraglutide. read more
Transcept's low-dose zolpidem for middle-of-the-night awakenings may need additional studies, including driving tests. read more
"The Pink Sheet" DAILY is the leading on-line news and analysis service for the pharmaceutical industry. For information about a subscription or to sign up for a free trial at www.thepinksheetdaily.com.
